Predict your next investment

Peptinnovate company logo
HEALTHCARE | Drug Development
peptinnovate.com

See what CB Insights has to offer

Stage

Other Investors | Alive

About Peptinnovate

Peptinnovate is a drug development company that offers services in research and development of new therapies, targeting a range of immuno–inflammatory diseases. The company is based in Stevenage, England.

Peptinnovate Headquarter Location

Gunnels Wood Road

Stevenage, England, SG1 2FX,

United Kingdom

Latest Peptinnovate News

New chairman at BioTech Phico

Jun 29, 2021

New chairman at BioTech Phico Posted on June 29, 2021 by Jonathan Symcox share Phico Therapeutics, a biotechnology company developing a new generation of antibiotics to overcome antibacterial resistance, has appointed a new chairman. The appointment of Richard Nagle follows the company’s recent funding from the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to advance its antibacterial therapy. A total of £13.2 million funding could be made available – in addition to the £7m of funding led by the British Growth Fund – should the project progress successfully to Phase 1 clinical trials. Nagle is an experienced BioTech executive and has built and developed business solutions across the international biopharma sector. His focus on accelerating product development has led to successful company exits or IPO, including recent CEO director of Immune Regulation (now Revolo Biotherapeutics), an innovative platform focused on regulating the immune system. Previously, Nagle served as Non-Executive Director of Peptinnovate and as CEO of a number of successful drug delivery, biotechnology and medical device businesses. He takes over from Dr. Anthony Martin, who has been Phico’s Chair since 2010. Dr. Heather Fairhead, Phico founder and CEO, commented: “We are delighted to welcome Richard as Chair of our Board with his wealth of executive and commercial experience. “This will be invaluable in our next exciting phase as we exemplify SASPject technology in first-in-human intravenous studies and advance the science of antibacterial therapy. “I would like to thank our previous chair Dr Anthony Martin for his support and dedication over the last 11 years – his guidance has been instrumental in achieving our success.”  Nagle added: “This is an extremely exciting time for Phico Therapeutics, and I am delighted to be joining this dynamic business, which has been at the forefront of building technological solutions to antibacterial resistance. “I intend to expand our presence both in the UK and Internationally. It is clear that Phico has built a world class team to execute on its clinical development goals and I look forward to working with Dr. Heather Fairhead and the management team in helping them to realise a number of great milestones for the company.”

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Peptinnovate Patents

Peptinnovate has filed 3 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/14/2014

4/26/2016

Proteins, Heat shock proteins, G protein coupled receptors, Inflammations, Molecular biology

Grant

Application Date

5/14/2014

Grant Date

4/26/2016

Title

Related Topics

Proteins, Heat shock proteins, G protein coupled receptors, Inflammations, Molecular biology

Status

Grant

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.